Aisling Capital related stories
All articles and analysis
Braunstein joins Aisling Capital as Operating PartnerDr. Scott Braunstein has joined Aisling Capital as an Operating Partner. Dr. Braunstein serves as Senior Vice President, Strategy and Corporate Development at Pacira Pharmaceuticals.
PSERS expands co-investment, secondaries program by $50 mlnThe Pennsylvania Public School Employees’ Retirement System allocated up to $250 million to private equity strategies at its Aug. 6 meeting, according to a series of announcements released on its website.
- VC-backed Aimmune Therapeutics goes public
Brisbane, California-based Aimmune Therapeutics, a biopharmaceutical company focused on treating peanut allergies, has raised $160 million for its IPO after pricing its 10 million shares at $16 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "AIMT." BofA Merrill Lynch, Credit Suisse and Piper Jaffray are serving as the lead underwriters. Aimmune's backers include Longitude Capital, Foresite Capital and Aisling Capital.
VC-backed Cynapsus Therapeutics sees IPO raising up to $67 mlnCynapsus Therapeutics Inc has set the terms of its previously announced initial public offering /canada/2015/05/19/venture-backed-cynapsus-therapeutics-files-for-nasdaq-ipo/ on the NASDAQ. The company plans to sell 4.5 million common shares and, potentially, a further 675,000 shares in an option granted to underwriters. At a recently quoted price per share of US$14.18, a filing with the U.S. Securities and Exchange Commission suggests the company expects to generate up to US$67.2 million. Based in Toronto, Cynapsus is a maker of drugs to treat patients suffering from Parkinson’s disease. It is backed by U.S. venture capital firms OrbiMed Advisors, Aisling Capital and Venrock.
Venture-backed Cynapsus Therapeutics files for NASDAQ IPOCanadian specialty pharmaceutical company Cynapsus Therapeutics Inc has registered with U.S. securities regulators and filed an application to list on the NASDAQ Capital Market. The timing, number of shares and price per share of the proposed offering have not yet been determined. Renaissance Capital has reported that the company is seeking to raise http://www.renaissancecapital.com/news/parkinsons-biotech-cynapsus-therapeutics-files-for-a-%2460-million-us-ipo-31496.html proceeds of up to US$60 million. Cynapsus, a Toronto-based maker of drugs to treat patients suffering from Parkinson’s disease, last month received almost $21 million in a financing deal /canada/2015/04/07/cynapsus-therapeutics-raises-21-mln-in-deal-led-by-orbimed-aisling-venrock/ led by U.S. venture capital firms OrbiMed Advisors, Aisling Capital and Venrock. It currently trades on the Toronto Stock Exchange.
- Venrock, Aisling Capital lead $18.5 mln round for Spirox
Spirox Inc. said Monday it closed an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round. Menlo Park, California-based Spirox is a medical device company focused on developing minimally invasive technologies to treat nasal obstruction.
- VC-backed Cidara Therapeutics rolls out IPO
San Diego-based biotech company Cidara Therapeutics has raised $76.8 million for its IPO after pricing its 4.8 million shares at $16 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol "CDTX." Jefferies LLC and Leerink Partners are the lead underwriters. Cidara’s backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.
Top Canadian VC deals from the first quarterIn the coming weeks, the Canadian Venture Capital & Private Equity Association (CVCA) and Thomson Reuters will issue their reports on Canadian venture capital market activity in the first quarter of 2015. In the meantime, peHUB Canada has compiled a list of the likely top 10 (disclosed) financings completed between January and March.
Cynapsus Therapeutics raises $21 mln in deal led by U.S. VCsCanadian specialty pharmaceutical company Cynapsus Therapeutics Inc (TSX: CTH) recently completed a private placement that generated gross proceeds of nearly $21 million. The financing was led by U.S. venture capital firms OrbiMed Advisors, Aisling Capital and Venrock and was joined by existing backers Broadfin Capital, Sphera Funds Management, Pura Vida Investments, DAFNA Capital Management and Dexcel Pharma Technologies Ltd, among others. The Toronto-based Cynapsus, which was founded in 2004, said the funds will help it to undertake Phase 3 clinical studies for a drug candidate to be used to treat patients suffering from Parkinson’s disease.
- VC-backed Cidara Therapeutics files for IPO
San Diego-based biotech company Cidara Therapeutics has filed for a $69 million IPO, according to an SEC filing http://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130ds1.htm The company plans on trading on the NASDAQ under the ticker symbol "CDTX." Jefferies and Leerink Partners are listed as lead underwriters. Cidara's backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.